# A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults

> **NCT06173596** · PHASE1 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ALXN2080
- **DRUG:** Itraconazole
- **DRUG:** Fluconazole (AxMP)
- **DRUG:** Carbamazepine (AxMP)

## Key facts

- **NCT ID:** NCT06173596
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-10
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-05-16
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06173596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06173596, "A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06173596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*